Can-Fite Expands the Out-Licensing Deal With Ewopharma to Include the Pancreatic Cancer Indication
Can-Fite Expands the Out-Licensing Deal With Ewopharma to Include the Pancreatic Cancer Indication
Can-Fite擴大了與Ewopharma的外包許可協議，將胰腺癌適應症包括在內
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the pancreatic cancer indication of Can-Fite.
Can-Fite BioPharma Ltd.（紐約證券交易所代碼：CANF）（TASE: CANF）是一家推進針對腫瘤和炎症性疾病的專有小分子藥物管道的生物技術公司，今天宣佈已擴大與Ewopharma AG. 的對外許可交易，將Can-Fite的胰腺癌適應症包括在內。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。